Immunotherapy, Tumor Microenvironment and Survival Signaling

The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies ha...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Formaat: Online
Taal:Engels
Gepubliceerd in: MDPI - Multidisciplinary Digital Publishing Institute 2022
Onderwerpen:
Online toegang:ONIX_20220706_9783036544199_67
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
_version_ 1869518045206020096
collection Directory of Open Access Books
description The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer.
format Online
id doab-20.500.12854ir-87472
institution Directory of Open Access Books
language eng
publishDate 2022
publishDateRange 2022
publishDateSort 2022
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-874722024-03-31T13:10:34Z Immunotherapy, Tumor Microenvironment and Survival Signaling Golubovskaya, Vita Autophagy colorectal cancer immunotherapy tumor stroma tumor microenvironment immune checkpoint inhibitors chemotherapy tyrosine kinase inhibitors angiogenesis check point inhibitors programmed cell death protein 1 programmed cell death 1 ligand 1 cardiotoxicity lung metastasis CAR-T hypoxia tumor microenvironment CD19 BCMA cancer melanoma immune escape antigen loss chimeric antigen receptor electroporation lentivirus lentiviral transduction macrophages leukemia cells lytic peptides targeted therapy dendritic cells pathogenesis risk factors breast cancer resistance checkpoint targeted treatment personalized medicine pediatric solid tumors chimeric antigen receptors cancer vaccines oncolytic viral therapy immunomodulation DCLK1 tumor stem cells clonogenicity mitochondria mitochondrial transfer tunneling nanotubes triple-negative breast cancer immune checkpoint inhibitor combination therapy cancer nanomedicine tumor antigens cancer metabolism cancer immunotherapy nanoparticles immunotherapeutic agent immunomodulators tuft cells cancer stem cells immunotherapies myeloid-derived suppressor cells regulatory T cells crosstalk tumor immune evasion cell–cell contact β2 integrins CD18 CD11 CAR-T cells CD37 cell therapy tumor antigen lymphoma CAR macrophage CAR T cell solid tumors immunometabolism miRNA immunogenic cell death n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer. 2022-07-06T11:51:24Z 2022-07-06T11:51:24Z 2022 book ONIX_20220706_9783036544199_67 9783036544199 9783036544205 https://directory.doabooks.org/handle/20.500.12854/87472 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/5660 https://mdpi.com/books/pdfview/book/5660 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-4420-5 10.3390/books978-3-0365-4420-5 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036544199 9783036544205 376 Basel open access
spellingShingle Autophagy
colorectal cancer
immunotherapy
tumor stroma
tumor microenvironment
immune checkpoint inhibitors
chemotherapy
tyrosine kinase inhibitors
angiogenesis
check point inhibitors
programmed cell death protein 1
programmed cell death 1 ligand 1
cardiotoxicity
lung metastasis
CAR-T
hypoxia
tumor
microenvironment
CD19
BCMA
cancer
melanoma
immune escape
antigen loss
chimeric antigen receptor
electroporation
lentivirus
lentiviral transduction
macrophages
leukemia cells
lytic peptides
targeted therapy
dendritic cells
pathogenesis
risk factors
breast cancer
resistance
checkpoint
targeted treatment
personalized medicine
pediatric solid tumors
chimeric antigen receptors
cancer vaccines
oncolytic viral therapy
immunomodulation
DCLK1
tumor stem cells
clonogenicity
mitochondria
mitochondrial transfer
tunneling nanotubes
triple-negative breast cancer
immune checkpoint inhibitor
combination therapy
cancer nanomedicine
tumor antigens
cancer metabolism
cancer immunotherapy
nanoparticles
immunotherapeutic agent
immunomodulators
tuft cells
cancer stem cells
immunotherapies
myeloid-derived suppressor cells
regulatory T cells
crosstalk
tumor immune evasion
cell–cell contact
β2 integrins
CD18
CD11
CAR-T cells
CD37
cell therapy
tumor antigen
lymphoma
CAR macrophage
CAR T cell
solid tumors
immunometabolism
miRNA
immunogenic cell death
n/a
thema EDItEUR::M Medicine and Nursing
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine
Immunotherapy, Tumor Microenvironment and Survival Signaling
title Immunotherapy, Tumor Microenvironment and Survival Signaling
title_full Immunotherapy, Tumor Microenvironment and Survival Signaling
title_fullStr Immunotherapy, Tumor Microenvironment and Survival Signaling
title_full_unstemmed Immunotherapy, Tumor Microenvironment and Survival Signaling
title_short Immunotherapy, Tumor Microenvironment and Survival Signaling
title_sort immunotherapy tumor microenvironment and survival signaling
topic Autophagy
colorectal cancer
immunotherapy
tumor stroma
tumor microenvironment
immune checkpoint inhibitors
chemotherapy
tyrosine kinase inhibitors
angiogenesis
check point inhibitors
programmed cell death protein 1
programmed cell death 1 ligand 1
cardiotoxicity
lung metastasis
CAR-T
hypoxia
tumor
microenvironment
CD19
BCMA
cancer
melanoma
immune escape
antigen loss
chimeric antigen receptor
electroporation
lentivirus
lentiviral transduction
macrophages
leukemia cells
lytic peptides
targeted therapy
dendritic cells
pathogenesis
risk factors
breast cancer
resistance
checkpoint
targeted treatment
personalized medicine
pediatric solid tumors
chimeric antigen receptors
cancer vaccines
oncolytic viral therapy
immunomodulation
DCLK1
tumor stem cells
clonogenicity
mitochondria
mitochondrial transfer
tunneling nanotubes
triple-negative breast cancer
immune checkpoint inhibitor
combination therapy
cancer nanomedicine
tumor antigens
cancer metabolism
cancer immunotherapy
nanoparticles
immunotherapeutic agent
immunomodulators
tuft cells
cancer stem cells
immunotherapies
myeloid-derived suppressor cells
regulatory T cells
crosstalk
tumor immune evasion
cell–cell contact
β2 integrins
CD18
CD11
CAR-T cells
CD37
cell therapy
tumor antigen
lymphoma
CAR macrophage
CAR T cell
solid tumors
immunometabolism
miRNA
immunogenic cell death
n/a
thema EDItEUR::M Medicine and Nursing
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine
topic_facet Autophagy
colorectal cancer
immunotherapy
tumor stroma
tumor microenvironment
immune checkpoint inhibitors
chemotherapy
tyrosine kinase inhibitors
angiogenesis
check point inhibitors
programmed cell death protein 1
programmed cell death 1 ligand 1
cardiotoxicity
lung metastasis
CAR-T
hypoxia
tumor
microenvironment
CD19
BCMA
cancer
melanoma
immune escape
antigen loss
chimeric antigen receptor
electroporation
lentivirus
lentiviral transduction
macrophages
leukemia cells
lytic peptides
targeted therapy
dendritic cells
pathogenesis
risk factors
breast cancer
resistance
checkpoint
targeted treatment
personalized medicine
pediatric solid tumors
chimeric antigen receptors
cancer vaccines
oncolytic viral therapy
immunomodulation
DCLK1
tumor stem cells
clonogenicity
mitochondria
mitochondrial transfer
tunneling nanotubes
triple-negative breast cancer
immune checkpoint inhibitor
combination therapy
cancer nanomedicine
tumor antigens
cancer metabolism
cancer immunotherapy
nanoparticles
immunotherapeutic agent
immunomodulators
tuft cells
cancer stem cells
immunotherapies
myeloid-derived suppressor cells
regulatory T cells
crosstalk
tumor immune evasion
cell–cell contact
β2 integrins
CD18
CD11
CAR-T cells
CD37
cell therapy
tumor antigen
lymphoma
CAR macrophage
CAR T cell
solid tumors
immunometabolism
miRNA
immunogenic cell death
n/a
thema EDItEUR::M Medicine and Nursing
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine
url ONIX_20220706_9783036544199_67